Literature DB >> 10383536

The management of Pneumocystis carinii pneumonia.

F J Vilar1, S H Khoo, T Walley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10383536      PMCID： PMC2014249          DOI： 10.1046/j.1365-2125.1999.00966.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  20 in total

1.  Opportunistic infections shortly after beginning highly active antiretroviral therapy.

Authors:  R Rodríguez-Rosado; V Soriano; C Dona; J González-Lahoz
Journal:  Antivir Ther       Date:  1998

2.  A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; F R Sattler; J Chiu; A W Wu; D Gluckstein; C Kemper; A Bartok; J Niosi; I Abramson; J Coffman
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

3.  Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.

Authors:  W M El-Sadr; R L Murphy; T M Yurik; R Luskin-Hawk; T W Cheung; H H Balfour; R Eng; T M Hooton; T M Kerkering; M Schutz; C van der Horst; R Hafner
Journal:  N Engl J Med       Date:  1998-12-24       Impact factor: 91.245

4.  Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS)

Authors:  J S Montaner; L M Lawson; N Levitt; A Belzberg; M T Schechter; J Ruedy
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

5.  Acute respiratory failure secondary to Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A potential role for systemic corticosteroids.

Authors:  J S Montaner; J A Russell; L Lawson; J Ruedy
Journal:  Chest       Date:  1989-04       Impact factor: 9.410

Review 6.  Acute respiratory failure due to Pneumocystis carinii pneumonia.

Authors:  K R Brooks; R Ong; R S Spector; D M Greenbaum
Journal:  Crit Care Clin       Date:  1993-01       Impact factor: 3.598

7.  CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.

Authors:  H Masur; F P Ognibene; R Yarchoan; J H Shelhamer; B F Baird; W Travis; A F Suffredini; L Deyton; J A Kovacs; J Falloon
Journal:  Ann Intern Med       Date:  1989-08-01       Impact factor: 25.391

8.  Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  M N Dohn; R P Baughman; E M Vigdorth; D L Frame
Journal:  Arch Intern Med       Date:  1992-12

Review 9.  Adjuvant corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS patients.

Authors:  C J Sistek; C J Wordell; S P Hauptman
Journal:  Ann Pharmacother       Date:  1992-09       Impact factor: 3.154

10.  A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.

Authors:  W D Hardy; J Feinberg; D M Finkelstein; M E Power; W He; C Kaczka; P T Frame; M Holmes; H Waskin; R J Fass
Journal:  N Engl J Med       Date:  1992-12-24       Impact factor: 91.245
View more
  4 in total

1.  Aetiology and prognosis of community-acquired pneumonia at the Adult University Teaching Hospital in Zambia.

Authors:  L M Ziko; T W Hoffman; S Fwoloshi; D Chanda; Y M Nampungwe; D Patel; H Bobat; A Moonga; L Chirwa; L Hachaambwa; K J Mateyo
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

2.  Pharmacokinetic study of azithromycin with fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole) in healthy volunteers.

Authors:  G W Amsden; G Foulds; K Thakker
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

3.  In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.

Authors:  E M Aliouat; E Dei-Cas; N Gantois; M Pottier; C Pinçon; S Hawser; A Lier; D B Huang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-12       Impact factor: 3.267

4.  Retrospective evaluation of cotrimoxazole use as preventive therapy in people living with HIV/AIDS in Boru Meda Hospital.

Authors:  Berhanu Geresu; Desye Misganaw; Yeshiwork Beyene
Journal:  BMC Pharmacol Toxicol       Date:  2014-02-08       Impact factor: 2.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.